Testing effectiveness (Phase 2)Enrolling By InvitationNCT07226297
What this trial is testing
Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charcot-Marie-Tooth Disease Type 2D (CMT2D)
Who this might be right for
Charcot-Marie-Tooth Disease Type 2D
n-Lorem Foundation 1